Image Source: Pexels

This comes from our MicroMarvel series of articles highlighting undercovered stocks with less than a billion dollars in Market Capitalization. These articles are not intended to be buy recommendations. They highlight stocks that may have limited trading volume and may be highly volatile, so if you do decide to add them to your portfolio I highly recommend you use stop losses and limit orders.

Today's MicroMarvel is the cancer research biopharma company Zymeworks (ZYME). I found the stock by using Barchart's screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum, and having a Trend Seeker buy signal, then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 2/1 the stock gained 11.82%.

• 100% technical buy signals
• 15 new highs and up 24.39% in the last month
• 65.09+ Weighted Alpha

ZYME Price vs Daily Moving Averages (Barchart)

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. 

Barchart Technical Indicators:

• 100% technical buy signals
• 65.09+ Weighted Alpha
• 42.58% gain in the last year
• Trend Seeker buy signal
• Above its 20, 50, and 100-day moving averages
• 15 new highs and up 24.39% in the last month
• Relative Strength Index 68.85%
• Technical support level at $11.69
• Recently traded at $12.06 with a 50-day moving average of $10.51

Fundamental Factors:

• Market Cap $841 million
• Wall Street projected Revenue will decrease 80.80% this year and grow again 44.10% next year
• Earnings are estimated to decrease 204.70% this year but increase 38.70% next year and continue to compound at an annual rate of 11.00R for the next 5 years

Analysts and Investor Sentiment -- I don't buy stocks just because everyone else is buying, but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:

• Wall Street issued 6 strong buy, and 3 hold recommendations on the stock
• Their price targets are between $8 and $19 with a consensus of $13.347for a gain of 2%
• Value Line rates the stock its above average rating of 2
• CFRAs Market Scope rates the stock a buy
• 5,650 investors monitor the stock on Seeking Alpha

More By This Author:

Chart Of The Day: SPX Technologies - Building Products For The Future
Byrna Technologies - Crime Stopper
Chart Of The Day: Should You Bet On DraftKings?